Infinity Pharmaceuticals sees 2013 net loss $115M-$125M Consensus for FY13 EPS is ($3.04). The company said it entered 2013 with approximately $327M in cash and investments. Infinity expects operating expenses for 2013 to range from $115M-$125M, net loss for 2013 to range from $115M-$125M and expects to end 2013 with a year-end cash and investments balance ranging from $210M-$220M. Based on its current operating plan and exclusive of any business development activities, Infinity’s financial foundation provides a cash runway into 2015, the company said.
UBS to hold a conference Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 18 at 8 am; not all company presentations may be webcasted. Webcast Link